Roberta Zappasodi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Roberta Zappasodi has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Taha Merghoub
Swim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Weill Cornell Medicine, New York, USA
42 shared publications - Jedd D. Wolchok
Parker Institute for Cancer Immunotherapy and Sandra and Edward Meyer Cance, Weill Cornell Medicine, New York, United States of America
32 shared publications Jingjing Qi
22 shared publications- Phillip Wong
Immune Monitoring Facility, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, USA
22 shared publications Todd Bauer
22 shared publicationsWalter Newman
22 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by Springer Nature in Nature Cell Biology
- Vol. 28 (11) , 2231-2247
Motile vesicles (MoVes) are a cancer cell migration-associated extracellular vesicle population
Migrating cancer cells release diverse extracellular vesicles (EVs) that carry cargo capable of influencing tumour progression and intercellular communication. However, the mechanisms by which intracellular components are incorporated into EVs remain poorly understood. Here we identify and characterize a previously undescribed population of large EVs (2–5 μm), termed motile vesicles (MoVes), that are generated during active cancer cell migration and associated with epithelial–mesenchymal transition. Comparative analyses across EV populations show that MoVes display distinct ultrastructural features, molecular composition and sedimentation behaviour. Live-cell imaging and scanning electron microscopy reveal that MoVes arise from trailing-edge retraction during mesenchymal migration and are actively shed by cancer cells but rarely by non-transformed cells. MoVes contain genomic DNA spanning the genome of the parent cell, recapitulating its mutational landscape, as well as organelles and proteins associated with epithelial–mesenchymal transition. Moreover, MoVes-associated mitochondrial cargo can enhance oxidative phosphorylation in recipient cells. Together, these findings identify MoVes as a cancer cell migration-associated EV population capable of disseminating genomic DNA and organelles.
- 28 October 2026
- Published by Springer Nature in Nature Cell Biology
- Vol. 28 (11) , 2231-2247
Open AccessMotile vesicles (MoVes) are a cancer cell migration-associated extracellular vesicle population
Migrating cancer cells release diverse extracellular vesicles (EVs) that carry cargo capable of influencing tumour progression and intercellular communication. However, the mechanisms by which intracellular components are incorporated into EVs remain poorly understood. Here we identify and characterize a previously undescribed population of large EVs (2–5 μm), termed motile vesicles (MoVes), that are generated during active cancer cell migration and associated with epithelial–mesenchymal transition. Comparative analyses across EV populations show that MoVes display distinct ultrastructural features, molecular composition and sedimentation behaviour. Live-cell imaging and scanning electron microscopy reveal that MoVes arise from trailing-edge retraction during mesenchymal migration and are actively shed by cancer cells but rarely by non-transformed cells. MoVes contain genomic DNA spanning the genome of the parent cell, recapitulating its mutational landscape, as well as organelles and proteins associated with epithelial–mesenchymal transition. Moreover, MoVes-associated mitochondrial cargo can enhance oxidative phosphorylation in recipient cells. Together, these findings identify MoVes as a cancer cell migration-associated EV population capable of disseminating genomic DNA and organelles.
- Open Access
A tumor metabolism-angiogenesis-immune axis governs immunotherapy responses
Despite the clinical success of immunotherapy, long-lasting benefit remains restricted to a subset of patients. Tumor metabolic adaptation is emerging as a key factor limiting immunotherapy efficacy. We previously found that glycolysis-low tumor variants, compared to the parental glycolytic tumors, better respond to neoadjuvant CTLA-4 immune checkpoint blockade (ICB) therapy. Here, we investigated new rational modalities to restore immune sensitivity of glycolytic tumors by studying how lowering the tumor-cell glycolytic capacity reshapes the tumor microenvironment (TME) to favor long-lasting systemic anti-tumor responses upon immunotherapy. We found that lowering glycolysis in cancer cells through LDHA-knock down (KD) results in TME displaying normalized vasculature, reduced angiogenic markers, increased high endothelial venules (HEVs), and enhanced recirculation of CD8 + T cells both in and out of the tumor. By leveraging public transcriptomic data sets from human solid cancers, we confirmed that glycolysis positively correlates with neo-angiogenesis and inversely correlates with features of vascular normalization and immune cytolytic activity. Moreover, a tumor signature that incorporates glycolysis- and angiogenesis-related genes as positive features, and normal vasculature, HEV, and immune cytolytic activity genes as negative features predicted poor outcomes better than the individual features across most human solid tumor types in the TCGA. To determine the therapeutic implication of these interrelated processes, we asked if targeting the vasculature would restore immunotherapy responses in glycolytic tumors. We found that combining low-dose anti-VEGFR2 with CTLA-4 blockade induces tumor regressions and protection from metastases in glycolytic tumors. These therapeutic effects were associated with vasculature normalization and increased abundance of HEVs and concentrations of lymphangiogenic factors in the TME of glycolytic tumors. Moreover, anti-VEGFR2 with anti-CTLA-4 restored recirculation of anti-tumor CD8 + T cells in and out of the TME in glycolytic tumors, with specific increases in intratumoral recruitment and activation of cytolytic CD62L⁺CD44⁺CD8⁺ T cells expressing VEGFR2 and low levels of CTLA-4, suggesting potential novel direct synergistic effects of anti-VEGFR2 and anti-CTLA-4 on CD8 + T cells. Conversely, this combination opposed the beneficial immune and vascular TME features of LDHA-KD tumors, indicating tumor-metabolic-dependent effects. Accordingly, we found that standard combined regimens of anti-VEGF and ICB therapy improve survival with respect to ICB alone in patients with glycolysis-high but not glycolysis-low tumors. Together, these findings indicate that tumor cell glycolysis “primes” the TME for aberrant vascular architecture and T-cell exclusion, and that modulating the tumor vasculature can unravel these mechanisms restoring immune responsiveness. This suggests that tailoring anti-angiogenic and immunotherapy combinations to the tumor glycolytic state and associated vasculature profiles may restore immune surveillance and overcome therapy resistance.
Open AccessA tumor metabolism-angiogenesis-immune axis governs immunotherapy responses
Despite the clinical success of immunotherapy, long-lasting benefit remains restricted to a subset of patients. Tumor metabolic adaptation is emerging as a key factor limiting immunotherapy efficacy. We previously found that glycolysis-low tumor variants, compared to the parental glycolytic tumors, better respond to neoadjuvant CTLA-4 immune checkpoint blockade (ICB) therapy. Here, we investigated new rational modalities to restore immune sensitivity of glycolytic tumors by studying how lowering the tumor-cell glycolytic capacity reshapes the tumor microenvironment (TME) to favor long-lasting systemic anti-tumor responses upon immunotherapy. We found that lowering glycolysis in cancer cells through LDHA-knock down (KD) results in TME displaying normalized vasculature, reduced angiogenic markers, increased high endothelial venules (HEVs), and enhanced recirculation of CD8 + T cells both in and out of the tumor. By leveraging public transcriptomic data sets from human solid cancers, we confirmed that glycolysis positively correlates with neo-angiogenesis and inversely correlates with features of vascular normalization and immune cytolytic activity. Moreover, a tumor signature that incorporates glycolysis- and angiogenesis-related genes as positive features, and normal vasculature, HEV, and immune cytolytic activity genes as negative features predicted poor outcomes better than the individual features across most human solid tumor types in the TCGA. To determine the therapeutic implication of these interrelated processes, we asked if targeting the vasculature would restore immunotherapy responses in glycolytic tumors. We found that combining low-dose anti-VEGFR2 with CTLA-4 blockade induces tumor regressions and protection from metastases in glycolytic tumors. These therapeutic effects were associated with vasculature normalization and increased abundance of HEVs and concentrations of lymphangiogenic factors in the TME of glycolytic tumors. Moreover, anti-VEGFR2 with anti-CTLA-4 restored recirculation of anti-tumor CD8 + T cells in and out of the TME in glycolytic tumors, with specific increases in intratumoral recruitment and activation of cytolytic CD62L⁺CD44⁺CD8⁺ T cells expressing VEGFR2 and low levels of CTLA-4, suggesting potential novel direct synergistic effects of anti-VEGFR2 and anti-CTLA-4 on CD8 + T cells. Conversely, this combination opposed the beneficial immune and vascular TME features of LDHA-KD tumors, indicating tumor-metabolic-dependent effects. Accordingly, we found that standard combined regimens of anti-VEGF and ICB therapy improve survival with respect to ICB alone in patients with glycolysis-high but not glycolysis-low tumors. Together, these findings indicate that tumor cell glycolysis “primes” the TME for aberrant vascular architecture and T-cell exclusion, and that modulating the tumor vasculature can unravel these mechanisms restoring immune responsiveness. This suggests that tailoring anti-angiogenic and immunotherapy combinations to the tumor glycolytic state and associated vasculature profiles may restore immune surveillance and overcome therapy resistance.
- 25 November 2025
- Published by Elsevier
- Vol. 202, 253-276
Flow-cytometry-based assay to study CD8+ T cell cytotoxicity against tumor cells
- 25 November 2025
- Published by Elsevier
- Vol. 202, 253-276
Flow-cytometry-based assay to study CD8+ T cell cytotoxicity against tumor cells
- 17 November 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (12) , 2296-2311
Thrombospondin-1–CD47 signaling contributes to the development of T cell exhaustion in cancer
T cell exhaustion is a major barrier to effective cancer immunotherapy. Although immune checkpoint blockade can reinvigorate exhausted T cells, not all patients achieve long-term responses, partly due to the refractory nature of terminally exhausted T cells. Beyond persistent antigen stimulation, the environmental drivers of exhaustion remain to be thoroughly characterized. Here we identify CD47 upregulation in tumor-infiltrating exhausted CD8+ T cells in both human and murine tumors. We reveal a novel role for the extracellular matrix protein thrombospondin-1 (TSP-1) in engaging CD47 on T cells to promote exhaustion. This interaction activates calcineurin–NFAT signaling, inducing upregulation of TOX and expression of inhibitory receptors, and impairing effector function during tumor progression. Importantly, disrupting the TSP-1–CD47 axis prevents T cell exhaustion and enhances tumor control. Our findings identify a novel pathway promoting T cell dysfunction and suggest that targeting the TSP-1–CD47 axis is a promising strategy to enhance T cell immunity and immunotherapy efficacy.
- 17 November 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (12) , 2296-2311
Thrombospondin-1–CD47 signaling contributes to the development of T cell exhaustion in cancer
T cell exhaustion is a major barrier to effective cancer immunotherapy. Although immune checkpoint blockade can reinvigorate exhausted T cells, not all patients achieve long-term responses, partly due to the refractory nature of terminally exhausted T cells. Beyond persistent antigen stimulation, the environmental drivers of exhaustion remain to be thoroughly characterized. Here we identify CD47 upregulation in tumor-infiltrating exhausted CD8+ T cells in both human and murine tumors. We reveal a novel role for the extracellular matrix protein thrombospondin-1 (TSP-1) in engaging CD47 on T cells to promote exhaustion. This interaction activates calcineurin–NFAT signaling, inducing upregulation of TOX and expression of inhibitory receptors, and impairing effector function during tumor progression. Importantly, disrupting the TSP-1–CD47 axis prevents T cell exhaustion and enhances tumor control. Our findings identify a novel pathway promoting T cell dysfunction and suggest that targeting the TSP-1–CD47 axis is a promising strategy to enhance T cell immunity and immunotherapy efficacy.
- 17 October 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (11)
Women in STEM becoming independent: Put science and discovery ahead of your ego
This year at JEM, we are highlighting women in science by sharing their stories and amplifying their voices. In this Viewpoint, we hear from a cross section of women, across multiple research fields, discussing their science and the process of setting up a lab as an independent researcher.
- 17 October 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (11)
Women in STEM becoming independent: Put science and discovery ahead of your ego
This year at JEM, we are highlighting women in science by sharing their stories and amplifying their voices. In this Viewpoint, we hear from a cross section of women, across multiple research fields, discussing their science and the process of setting up a lab as an independent researcher.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
Baseline demographics and characteristics.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
Baseline demographics and characteristics.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
A, Frequencies of Tregs. B, Changes in central memory (CM) and EM CD4+ T cells.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
A, Frequencies of Tregs. B, Changes in central memory (CM) and EM CD4+ T cells.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
A, INCAGN01876 mean (±SE) concentration–time profiles after the first dose and at steady state. B, Relationship between serum concentrations of INCAGN01876 and GITR receptor occupancy. C, Percentage of INCAGN01876 receptor occupancy vs. time. The average receptor occupancy per cohort is depicted (± SD). PK analysis includes patients with ADA-negative status at the respective visit; first visit/steady state: 0.03 mg/kg, n = 4/n = 0; 0.1 mg/kg, n = 4/n = 0; 0.3 mg/kg, n = 3/n = 1; 1 mg/kg, n = 3/n = 1; 3 mg/kg, n = 15/n = 5; 5 mg/kg, n = 16/n = 5; 10 mg/kg, n = 14/n = 4; 20 mg/kg, n = 3/n = 0; 300 mg, n = 21/n = 7; and 400 mg, n = 9/n = 3. RO, receptor occupancy.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
A, INCAGN01876 mean (±SE) concentration–time profiles after the first dose and at steady state. B, Relationship between serum concentrations of INCAGN01876 and GITR receptor occupancy. C, Percentage of INCAGN01876 receptor occupancy vs. time. The average receptor occupancy per cohort is depicted (± SD). PK analysis includes patients with ADA-negative status at the respective visit; first visit/steady state: 0.03 mg/kg, n = 4/n = 0; 0.1 mg/kg, n = 4/n = 0; 0.3 mg/kg, n = 3/n = 1; 1 mg/kg, n = 3/n = 1; 3 mg/kg, n = 15/n = 5; 5 mg/kg, n = 16/n = 5; 10 mg/kg, n = 14/n = 4; 20 mg/kg, n = 3/n = 0; 300 mg, n = 21/n = 7; and 400 mg, n = 9/n = 3. RO, receptor occupancy.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Data from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
Purpose:Glucocorticoid-induced tumor necrosis factor receptor–related protein (GITR) agonism in T cells may potentiate antitumor immune responses to immune checkpoint blockade therapy. This first-in-human, phase I/II dose escalation/expansion study assessed INCAGN01876, a humanized GITR-targeting agonistic mAb, for advanced solid tumors (NCT02697591).Patients and Methods:Dose was escalated by 0.03 to 20 mg/kg every 2 weeks; flat doses of 400 mg every 4 weeks and 300 mg every 2 weeks were also evaluated. The primary objective was safety/tolerability; secondary objectives were pharmacokinetics and preliminary efficacy; and exploratory objectives were immunogenicity, GITR occupancy, and immune biomarker assessment.Results:Among 100 patients enrolled [prior anti–PD-1/PD-L1 therapy, 47%; most common tumors: colorectal (19%) and melanoma (14%)], 2% had one dose-limiting toxicity (grade 4 hypoxia and grade 3 pleurisy). The MTD was not reached. Treatment-related adverse events (TRAE) occurred in 69% of patients, most frequently fatigue (17%) and pruritus (14%); 10% had grade ≥3 TRAEs, most commonly fatigue (3%); and 23% reported immune-related adverse events, most frequently generalized pruritus and generalized rash (7% each). Doses ≥5 mg/kg every 2 weeks resulted in full receptor occupancy at trough. INCAGN01876 elicited changes in immune parameters in some patients, including variable peripheral regulatory T-cell depletion and cytokine upregulation. Two patients achieved confirmed partial responses: one with appendiceal mucinous carcinoma and another with melanoma previously treated with pembrolizumab and glembatumumab; 36% of patients had disease control.Conclusions:INCAGN01876 was generally well tolerated; fatigue was the most frequent TRAE. INCAGN01876 elicited transient and variable regulatory T-cell depletion and limited antitumor activity. Future studies will explore combinatorial approaches.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
Purpose:Glucocorticoid-induced tumor necrosis factor receptor–related protein (GITR) agonism in T cells may potentiate antitumor immune responses to immune checkpoint blockade therapy. This first-in-human, phase I/II dose escalation/expansion study assessed INCAGN01876, a humanized GITR-targeting agonistic mAb, for advanced solid tumors (NCT02697591).Patients and Methods:Dose was escalated by 0.03 to 20 mg/kg every 2 weeks; flat doses of 400 mg every 4 weeks and 300 mg every 2 weeks were also evaluated. The primary objective was safety/tolerability; secondary objectives were pharmacokinetics and preliminary efficacy; and exploratory objectives were immunogenicity, GITR occupancy, and immune biomarker assessment.Results:Among 100 patients enrolled [prior anti–PD-1/PD-L1 therapy, 47%; most common tumors: colorectal (19%) and melanoma (14%)], 2% had one dose-limiting toxicity (grade 4 hypoxia and grade 3 pleurisy). The MTD was not reached. Treatment-related adverse events (TRAE) occurred in 69% of patients, most frequently fatigue (17%) and pruritus (14%); 10% had grade ≥3 TRAEs, most commonly fatigue (3%); and 23% reported immune-related adverse events, most frequently generalized pruritus and generalized rash (7% each). Doses ≥5 mg/kg every 2 weeks resulted in full receptor occupancy at trough. INCAGN01876 elicited changes in immune parameters in some patients, including variable peripheral regulatory T-cell depletion and cytokine upregulation. Two patients achieved confirmed partial responses: one with appendiceal mucinous carcinoma and another with melanoma previously treated with pembrolizumab and glembatumumab; 36% of patients had disease control.Conclusions:INCAGN01876 was generally well tolerated; fatigue was the most frequent TRAE. INCAGN01876 elicited transient and variable regulatory T-cell depletion and limited antitumor activity. Future studies will explore combinatorial approaches.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
Patient disposition. aTwo patients completed treatment [0.3 mg/kg every 2 weeks (Q2W) and 300 mg Q2W, respectively]. The death in the 300-mg Q2W cohort was coded as dyspnea secondary to disease progression. Reasons for patient ineligibility included meeting the following exclusion criteria: (i) laboratory and medical history parameters not within the protocol-defined range (39%; 17/44 patients); (ii) any condition that would, in the investigator’s judgment, interfere with full participation in the study (including administration of the study drug and attending required study visits), pose a significant risk to the subject, or interfere with the interpretation of study data (16%; 7/44 patients); (iii) known active central nervous system metastases and/or carcinomatous meningitis (14%; 6/44 patients); and (iv) evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection or risk of reactivation (positive testing for HBV DNA and/or HCV RNA; 11%; 5/44 patients) and not meeting the following inclusion criteria: willingness to provide a written informed consent form (7%; 3/44 patients) and having Eastern Cooperative Oncology Group performance status of 0 or 1 (5%; 2/44 patients). FAS, full analysis set.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
Patient disposition. aTwo patients completed treatment [0.3 mg/kg every 2 weeks (Q2W) and 300 mg Q2W, respectively]. The death in the 300-mg Q2W cohort was coded as dyspnea secondary to disease progression. Reasons for patient ineligibility included meeting the following exclusion criteria: (i) laboratory and medical history parameters not within the protocol-defined range (39%; 17/44 patients); (ii) any condition that would, in the investigator’s judgment, interfere with full participation in the study (including administration of the study drug and attending required study visits), pose a significant risk to the subject, or interfere with the interpretation of study data (16%; 7/44 patients); (iii) known active central nervous system metastases and/or carcinomatous meningitis (14%; 6/44 patients); and (iv) evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection or risk of reactivation (positive testing for HBV DNA and/or HCV RNA; 11%; 5/44 patients) and not meeting the following inclusion criteria: willingness to provide a written informed consent form (7%; 3/44 patients) and having Eastern Cooperative Oncology Group performance status of 0 or 1 (5%; 2/44 patients). FAS, full analysis set.